Sebastiano Mercadante

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2327159/publications.pdf

Version: 2024-02-01

349 papers 14,145 citations

25423 59 h-index 35168 102 g-index

355 all docs

355 docs citations

355 times ranked

7264 citing authors

#	Article	IF	CITATIONS
1	Palliative sedation outside a palliative care unit. BMJ Supportive and Palliative Care, 2023, 13, e297-e299.	0.8	4
2	Maddalena Opioid Switching Score in patients with cancer pain. Pain, 2023, 164, 91-97.	2.0	5
3	The use of complementary alternative medicines in advanced cancer patients followed at home. Supportive Care in Cancer, 2022, 30, 2003-2008.	1.0	3
4	Aberrant opioid use behaviour in advanced cancer. BMJ Supportive and Palliative Care, 2022, 12, 107-113.	0.8	4
5	Pattern and characteristics of patients admitted to a hospice connected with an acute palliative care unit in a comprehensive cancer center. Supportive Care in Cancer, 2022, 30, 2811-2819.	1.0	8
6	Methadone as First-line Opioid for the Management of Cancer Pain. Oncologist, 2022, 27, 323-327.	1.9	11
7	When the game is hard, more complex weapons are needed. BMJ Supportive and Palliative Care, 2022, , bmjspcare-2021-003518.	0.8	2
8	High-flow nasal OXYGEN therapy. BMJ Supportive and Palliative Care, 2022, , bmjspcare-2022-003606.	0.8	2
9	Response to Sarbey: Why Standard Drug Treatments for the "Death Rattle―Should Be Discontinued (DOI: 10.1089/jpm.2021.0568): Death Rattle in Dying Patients. Journal of Palliative Medicine, 2022, 25, 703-704.	0.6	1
10	Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study. Cancer Management and Research, 2022, Volume 14, 1237-1245.	0.9	4
11	Constipation in Cancer Patients — an Update of Clinical Evidence. Current Treatment Options in Oncology, 2022, 23, 936-950.	1.3	15
12	Caregiver Distress in Home Palliative Care. American Journal of Hospice and Palliative Medicine, 2022, 39, 1337-1341.	0.8	3
13	The need of a palliative care network. Supportive Care in Cancer, 2022, 30, 6381-6383.	1.0	4
14	Review of European Guidelines on Palliative Sedation: A Foundation for the Updating of the European Association for Palliative Care Framework. Journal of Palliative Medicine, 2022, 25, 1721-1731.	0.6	12
15	Financial distress and its impact on symptom expression in advanced cancer patients. Supportive Care in Cancer, 2021, 29, 485-490.	1.0	9
16	The lower the expectations in controlling the symptoms of advanced cancer patients, the better the clinical response. International Journal of Clinical Practice, 2021, 75, e13703.	0.8	0
17	Barriers and Adherence to Pain Management in Advanced Cancer Patients. Pain Practice, 2021, 21, 388-393.	0.9	12
18	Dual opioid therapy in a cancer patient with myasthenia gravis who developed respiratory depression from codeine. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2020-002745.	0.8	1

#	Article	IF	CITATIONS
19	Chronic cancer and non-cancer pain and opioid-induced hyperalgesia share common mechanisms: neuroinflammation and central sensitization. Minerva Anestesiologica, 2021, 87, 210-222.	0.6	15
20	Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain. Cancer Management and Research, 2021, Volume 13, 1747-1756.	0.9	2
21	Extreme opioid-induced constipation in advanced cancer: successful management. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-002981.	0.8	O
22	The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. Cancers, 2021, 13, 1058.	1.7	8
23	Practical Advices for Treating Chronic Pain in the Time of COVID-19: A Narrative Review Focusing on Interventional Techniques. Journal of Clinical Medicine, 2021, 10, 2303.	1.0	7
24	Factors Influencing Pain Expression in Patients with Cancer: An Expert Opinion. Pain and Therapy, 2021, 10, 765-775.	1.5	11
25	Immunity and pain: is it time for the birth of immunoalgology?. Minerva Anestesiologica, 2021, 87, 845-847.	0.6	1
26	A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study. Journal of Clinical Medicine, 2021, 10, 2273.	1.0	2
27	High flow nasal therapy in the management of hypoxemic dyspnea at the end of life. Supportive Care in Cancer, 2021, 29, 6179-6181.	1.0	3
28	Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel. Advances in Therapy, 2021, 38, 3589-3621.	1.3	19
29	Insomnia in patients with advanced lung cancer admitted to palliative care services. International Journal of Clinical Practice, 2021, 75, e14521.	0.8	2
30	Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study. Cancers, 2021, 13, 4018.	1.7	12
31	The Role of Religiosity in Symptom Expression of Advanced Cancer Patients. American Journal of Hospice and Palliative Medicine, 2021, , 104990912110413.	0.8	1
32	Understanding the Chameleonic Breakthrough Cancer Pain. Drugs, 2021, 81, 411-418.	4.9	12
33	Personalized goal for insomnia and clinical response in advanced cancer patients. Supportive Care in Cancer, 2020, 28, 1089-1096.	1.0	3
34	Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. Oncologist, 2020, 25, 156-160.	1.9	12
35	Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?. Current Medical Research and Opinion, 2020, 36, (I)-(XVII).	0.9	2
36	Effects of age and gender in patients receiving doses of opioids for breakthrough pain proportional to background opioid doses. Supportive Care in Cancer, 2020, 28, 3813-3818.	1.0	0

#	Article	IF	Citations
37	Association between alcoholism and symptom expression, patient symptom goals, and clinical response in advanced cancer patients. Supportive Care in Cancer, 2020, 28, 3361-3369.	1.0	2
38	Methadone versus morphine for postoperative pain in patients undergoing surgery for gynecological cancer: A randomized controlled clinical trial. Journal of Clinical Anesthesia, 2020, 61, 109627.	0.7	7
39	The Endless Question of Opioid Doses for Breakthrough Pain. Oncologist, 2020, 25, e1134-e1135.	1.9	1
40	Intractable pain and cordotomy. BMJ Supportive and Palliative Care, 2020, 10, 339-339.	0.8	0
41	The clash between palliative care and COVID-19. Supportive Care in Cancer, 2020, 28, 5593-5595.	1.0	4
42	Hospice care pathways and COVID-19. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002505.	0.8	3
43	The Potential Role of Dual Mechanistic Opioids in Combating Opioid Misuse. Current Anesthesiology Reports, 2020, 10, 416-422.	0.9	2
44	Episodic Breathlessness with and without Background Dyspnea in Advanced Cancer Patients Admitted to an Acute Supportive Care Unit. Cancers, 2020, 12, 2102.	1.7	4
45	Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. JCO Precision Oncology, 2020, 4, 1339-1349.	1.5	10
46	Devices or Care for Cancer Pain Management?. Anesthesia and Analgesia, 2020, 130, e151-e152.	1.1	2
47	Palliative Care in the Time of COVID-19. Journal of Pain and Symptom Management, 2020, 60, e79-e80.	0.6	46
48	Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study. Journal of Clinical Medicine, 2020, 9, 1337.	1.0	6
49	Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?. Current Medical Research and Opinion, 2020, 36, 1015-1024.	0.9	5
50	Challenges faced by the Italian medical workforce. Lancet, The, 2020, 395, e54.	6.3	1
51	Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study. Journal of Clinical Medicine, 2020, 9, 1003.	1.0	27
52	The Therapeutic Potential of Novel Kappa Opioid Receptor-based Treatments. Current Medicinal Chemistry, 2020, 27, 2012-2020.	1.2	6
53	Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients. Oncologist, 2019, 24, 239-246.	1.9	11
54	The use of alternative therapies in conjunction with opioids for cancer pain. Expert Review of Anticancer Therapy, 2019, 19, 697-703.	1.1	1

#	Article	IF	CITATIONS
55	Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study. Oral Oncology, 2019, 95, 87-90.	0.8	12
56	Reviewing without a Clinical Background Is Detrimental for Cancer Pain Management. Cancers, 2019, 11, 1005.	1.7	3
57	Personalized Pain Goals and Responses in Advanced Cancer Patients. Pain Medicine, 2019, 21, e215-e221.	0.9	3
58	Symptom Expression in Patients with Advanced Cancer Admitted to an Acute Supportive/Palliative Care Unit With and Without Delirium. Oncologist, 2019, 24, e358-e364.	1.9	6
59	Opioid-Induced Tolerance and Hyperalgesia. CNS Drugs, 2019, 33, 943-955.	2.7	144
60	Author's Response. Journal of Pain and Symptom Management, 2019, 57, e13-e14.	0.6	0
61	The Combination of Superior Hypogastric Plexus Block and the Block of the Ganglium Impair in a Patient With Abdominal and Perineal Pain Poorly Responsive to Opioids. Journal of Pain and Symptom Management, 2019, 58, e5-e8.	0.6	4
62	The Patient with Difficult Cancer Pain. Cancers, 2019, 11, 565.	1.7	20
63	Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain. Journal of Pain and Symptom Management, 2019, 57, 966-970.	0.6	6
64	Interventional Techniques for the Management of Cancer-Related Pain: Clinical and Critical Aspects. Cancers, $2019, 11, 443$.	1.7	28
65	Potential strategies to combat the opioid crisis. Expert Opinion on Drug Safety, 2019, 18, 211-217.	1.0	11
66	Pain Management in Patients with Multiple Myeloma: An Update. Cancers, 2019, 11, 2037.	1.7	38
67	Factors Influencing Clinical and Setting Pathways After Discharge From an Acute Palliative/Supportive Care Unit. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 265-269.	0.6	O
68	Standards for the management of cancerâ€related pain across Europeâ€"A position paper from the EFIC Task Force on Cancer Pain. European Journal of Pain, 2019, 23, 660-668.	1.4	67
69	Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPSâ€MS study. European Journal of Pain, 2019, 23, 719-726.	1.4	17
70	Author's Response. Journal of Pain and Symptom Management, 2019, 57, e17-e18.	0.6	0
71	Symptom hyper-expression in advanced cancer patients with anxiety and depression admitted to an acute supportive/palliative care unit. Supportive Care in Cancer, 2019, 27, 3081-3088.	1.0	15
72	Author's Response. Journal of Pain and Symptom Management, 2019, 57, e15-e16.	0.6	0

#	Article	IF	CITATIONS
73	Personalized Goal for Dyspnea and Clinical Response in Advanced Cancer Patients. Journal of Pain and Symptom Management, 2019, 57, 79-85.	0.6	5
74	Symptom expression in advanced cancer patients admitted to hospice or home care with and without delirium. Internal and Emergency Medicine, 2019, 14, 515-520.	1.0	7
75	Opioid Analgesics Adverse Effects: The Other Side of the Coin. Current Pharmaceutical Design, 2019, 25, 3197-3202.	0.9	28
76	Episodic Breathlessness inÂPatients with Advanced Cancer: Characteristics and Management. Drugs, 2018, 78, 543-547.	4.9	8
77	Treating breakthrough pain in oncology. Expert Review of Anticancer Therapy, 2018, 18, 445-449.	1.1	15
78	Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review. Critical Reviews in Oncology/Hematology, 2018, 122, 60-63.	2.0	12
79	Characteristics and care pathways of advanced cancer patients in a palliative-supportive care unit and an oncological ward. Supportive Care in Cancer, 2018, 26, 1961-1966.	1.0	6
80	The prevalence of constipation at admission and after 1 week of palliative care: a multi-center study. Current Medical Research and Opinion, 2018, 34, 1187-1192.	0.9	11
81	Prevalence of delirium in advanced cancer patients in home care and hospice and outcomes after 1Âweek of palliative care. Supportive Care in Cancer, 2018, 26, 913-919.	1.0	28
82	Attitudes towards end-of-life issues in intensive care unit among Italian anesthesiologists: a nation-wide survey. Supportive Care in Cancer, 2018, 26, 1773-1780.	1.0	23
83	Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review. Journal of Pain and Symptom Management, 2018, 55, 998-1003.	0.6	40
84	The use of ketamine in a palliative-supportive care unit: a retrospective analysis. Annals of Palliative Medicine, 2018, 7, 205-210.	0.5	10
85	Palliative ventilatory support: same knowledge, different goal. Journal of Thoracic Disease, 2018, 10, E236-E237.	0.6	3
86	Physicians' Attitudes Toward Euthanasia and Assisted Suicide in Italy. Journal of Pain and Symptom Management, 2018, 56, e1-e3.	0.6	3
87	Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later. Journal of Pain and Symptom Management, 2018, 56, 902-907.	0.6	32
88	Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients. Cancers, 2018, 10, 175.	1.7	44
89	The benefits of practical clinical trials over traditional randomized clinical trials for opioid management. Expert Review of Clinical Pharmacology, 2018, 11, 741-742.	1.3	3
90	Palliative care in intensive care units: why, where, what, who, when, how. BMC Anesthesiology, 2018, 18, 106.	0.7	131

#	Article	IF	CITATIONS
91	Attitudes of palliative home care physicians towards palliative sedation at home in Italy. Supportive Care in Cancer, 2017, 25, 1615-1620.	1.0	8
92	New drugs for pain management in advanced cancer patients. Expert Opinion on Pharmacotherapy, 2017, 18, 497-502.	0.9	7
93	Options for Treating Pain in Cancer Patients with Dysphagia. Drugs, 2017, 77, 629-635.	4.9	9
94	Characteristics of advanced cancer patients who were readmitted to an acute palliative/supportive care unit. Supportive Care in Cancer, 2017, 25, 1947-1952.	1.0	12
95	Characteristics of patients with an unplanned admission to an acute palliative care unit. Internal and Emergency Medicine, 2017, 12, 587-592.	1.0	10
96	Delirium assessed by Memorial Delirium Assessment Scale in advanced cancer patients admitted to an acute palliative/supportive care unit. Current Medical Research and Opinion, 2017, 33, 1303-1308.	0.9	24
97	Application of palliative ventilation: potential and clinical evidence in palliative care. Supportive Care in Cancer, 2017, 25, 2035-2039.	1.0	14
98	The effects of alcoholism and smoking on advanced cancer patients admitted to an acute supportive/palliative care unit. Supportive Care in Cancer, 2017, 25, 2147-2153.	1.0	7
99	Oxycodone extended release capsules for the treatment of chronic pain. Expert Review of Neurotherapeutics, 2017, 17, 427-431.	1.4	1
100	Fentanyl products in the management of episodic pain in the cancer patient. Expert Review of Quality of Life in Cancer Care, 2017, 2, 41-45.	0.6	0
101	Sleep disturbances in advanced cancer patients admitted to a supportive/palliative care unit. Supportive Care in Cancer, 2017, 25, 1301-1306.	1.0	40
102	The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review. Current Medical Research and Opinion, 2017, 33, 1965-1969.	0.9	12
103	The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids. Supportive Care in Cancer, 2017, 25, 645-649.	1.0	10
104	Obviousness in the dying patient. Internal and Emergency Medicine, 2017, 12, 137-137.	1.0	0
105	Background and episodic breathlessness in advanced cancer patients followed at home. Current Medical Research and Opinion, 2017, 33, 155-160.	0.9	13
106	Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). Advances in Therapy, 2017, 34, 120-135.	1.3	19
107	Opioid switching in cancer patients. Expert Review of Quality of Life in Cancer Care, 2016, 1, 443-447.	0.6	0
108	Breakthrough cancer pain: twenty-five years of study. Pain, 2016, 157, 2657-2663.	2.0	80

#	Article	IF	CITATIONS
109	Pattern of symptoms and symptomatic treatment in adults and the aged population: a retrospective analysis of advanced cancer patients followed at home. Current Medical Research and Opinion, 2016, 32, 893-898.	0.9	5
110	Breakthrough Cancer Pain: Ten Commandments. Value in Health, 2016, 19, 531-536.	0.1	17
111	Effect of aging on pain relief in the older cancer patients: pharmacokinetic and pharmacodynamic aspects. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 711-713.	1.5	1
112	Age differences in the last week of life in advanced cancer patients followed at home. Supportive Care in Cancer, 2016, 24, 1889-1895.	1.0	9
113	Author's Reply to Kawada. Journal of Pain and Symptom Management, 2016, 52, e4.	0.6	0
114	Supportive care services in hemato-oncology centers: a national survey. Supportive Care in Cancer, 2016, 24, 4407-4411.	1.0	2
115	Authors' Reply to Davies etÂal Journal of Pain and Symptom Management, 2016, 52, e1-e2.	0.6	2
116	Nurse-based monitoring and management of breakthrough pain in an acute pain relief and palliative care unit. Hospital Practice (1995), 2016, 44, 203-206.	0.5	2
117	Parenteral routes for opioid administration in cancer pain management. European Journal of Internal Medicine, 2016, 34, e39-e40.	1.0	6
118	Symptom burden in mesothelioma patients admitted to home palliative care. Current Medical Research and Opinion, 2016, 32, 1985-1988.	0.9	17
119	Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of ABreakthrough Cancer Pain: A Comparative Study. Journal of Pain and Symptom Management, 2016, 52, 27-34.	0.6	19
120	Minimally invasive procedures for the management of vertebral bone pain due to cancer: The EAPC recommendations. Acta Oncol \tilde{A}^3 gica, 2016, 55, 129-133.	0.8	10
121	The characteristics of advanced cancer patients followed at home, but admitted to the hospital for the last days of life. Internal and Emergency Medicine, 2016, 11, 713-718.	1.0	23
122	Attitudes Among Patients With Advanced Cancer Toward Euthanasia and Living Wills. Journal of Pain and Symptom Management, 2016, 51, e3-e6.	0.6	7
123	Unexpected Death on an Acute Palliative Care Unit. Journal of Pain and Symptom Management, 2016, 51, e1-e2.	0.6	4
124	From "Breakthrough―to "Episodic―Cancer Pain? A European Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations. Journal of Pain and Symptom Management, 2016, 51, 1013-1019.	0.6	65
125	Opioid switching in cancer pain: From the beginning to nowadays. Critical Reviews in Oncology/Hematology, 2016, 99, 241-248.	2.0	74
126	Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study. Journal of Pain and Symptom Management, 2016, 51, 17-24.	0.6	33

#	Article	IF	CITATIONS
127	Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic) Tj ETQq1 1	0.784314 1.0	rgBT /Overl
128	The Palliative-Supportive Care Unit in a Comprehensive Cancer Center as Crossroad for Patients' Oncological Pathway. PLoS ONE, 2016, 11, e0157300.	1.1	36
129	Author's Reply to Johnson and Noble. Journal of Pain and Symptom Management, 2015, 50, e2.	0.6	0
130	Pain Intensity as Prognostic Factor in Cancer Pain Management. Pain Practice, 2015, 15, E1-8.	0.9	19
131	Breakthrough pain in cancer patients. Current Opinion in Anaesthesiology, 2015, 28, 559-564.	0.9	49
132	Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Supportive Care in Cancer, 2015, 23, 1349-1354.	1.0	22
133	Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain. Expert Review of Clinical Pharmacology, 2015, 8, 9-13.	1.3	6
134	Opioid metabolism and clinical aspects. European Journal of Pharmacology, 2015, 769, 71-78.	1.7	56
135	The Frequency of Alcoholism in Patients With Advanced Cancer Admitted to an Acute Palliative Care Unit and a Home Care Program. Journal of Pain and Symptom Management, 2015, 49, 254-257.	0.6	12
136	The use of opioids for treatment of cancer pain. Expert Opinion on Pharmacotherapy, 2015, 16, 389-394.	0.9	12
137	Frequency and Indications of Parenteral Nutrition in an Acute Palliative Care Unit. Nutrition and Cancer, 2015, 67, 1010-1013.	0.9	8
138	Octreotide for Malignant Bowel Obstruction: Commentary on Currow et al. Journal of Pain and Symptom Management, 2015, 49, 813.	0.6	8
139	Pain Characteristics and Analgesic Treatment in an Aged Adult Population: A 4-Week Retrospective Analysis of Advanced Cancer Patients Followed at Home. Drugs and Aging, 2015, 32, 315-320.	1.3	12
140	Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Supportive Care in Cancer, 2015, 23, 2135-2143.	1.0	13
141	The bad luck of being old. Internal and Emergency Medicine, 2015, 10, 285-286.	1.0	2
142	Italian Oncological Pain Survey (IOPS). Clinical Journal of Pain, 2015, 31, 214-221.	0.8	53
143	Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Supportive Care in Cancer, 2015, 23, 3249-3255.	1.0	103
144	Sympathetic blocks for visceral cancer pain management: A systematic review and EAPC recommendations. Critical Reviews in Oncology/Hematology, 2015, 96, 577-583.	2.0	53

#	Article	IF	CITATIONS
145	Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional toÂtheÂBasal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study. Journal of Pain and Symptom Management, 2015, 50, 579-586.	0.6	40
146	Topical amitriptyline and ketamine for the treatment of neuropathic pain. Expert Review of Neurotherapeutics, 2015, 15, 1249-1253.	1.4	15
147	Good…but Bad News. Journal of Clinical Oncology, 2015, 33, 2119-2119.	0.8	8
148	Sleep Disturbances in Patients With Advanced Cancer in Different Palliative Care Settings. Journal of Pain and Symptom Management, 2015, 50, 786-792.	0.6	69
149	Assessing age and gender in studies of breakthrough pain medications. Current Medical Research and Opinion, 2014, 30, 1353-1356.	0.9	12
150	Classification of neuropathic pain in cancer patients: A Delphi expert survey report and EAPC/IASP proposal of an algorithm for diagnostic criteria. Pain, 2014, 155, 2707-2713.	2.0	32
151	Analgesic Treatment of Bone Metastases. Cancer Metastasis - Biology and Treatment, 2014, , 157-173.	0.1	0
152	Breakthrough Pain in Patients With Abdominal Cancer Pain. Clinical Journal of Pain, 2014, 30, 510-514.	0.8	18
153	Intranasal Fentanyl Versus Fentanyl Pectin Nasal Spray for the Management of Breakthrough Cancer Pain in Doses Proportional to Basal Opioid Regimen. Journal of Pain, 2014, 15, 602-607.	0.7	34
154	Managing Difficult Pain Conditions in the Cancer Patient. Current Pain and Headache Reports, 2014, 18, 395.	1.3	25
155	Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Current Medical Research and Opinion, 2014, 30, 2063-2068.	0.9	17
156	Efficacy and safety of dual opioid therapy. Expert Opinion on Drug Safety, 2014, 13, 1433-1436.	1.0	7
157	The pain, the oncologist. Supportive Care in Cancer, 2014, 22, 2021-2022.	1.0	0
158	New Opioids. Journal of Clinical Oncology, 2014, 32, 1671-1676.	0.8	18
159	Pharmacological management of cancer pain in children. Critical Reviews in Oncology/Hematology, 2014, 91, 93-97.	2.0	25
160	Palliative Sedation in Patients With Advanced Cancer Followed at Home: A Prospective Study. Journal of Pain and Symptom Management, 2014, 47, 860-866.	0.6	42
161	Cancer pain management in an oncological ward in a comprehensive cancer center with an established palliative care unit. Supportive Care in Cancer, 2013, 21, 3287-3292.	1.0	18
162	The poor use of methadone in Italian hospices. Supportive Care in Cancer, 2013, 21, 2225-2228.	1.0	5

#	Article	IF	Citations
163	The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Supportive Care in Cancer, 2013, 21, 2335-2339.	1.0	26
164	Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit. Supportive Care in Cancer, 2013, 21, 1853-1859.	1.0	11
165	Can a phone call be more effective than an intrathecal implanted pump?. Supportive Care in Cancer, 2013, 21, 1213-1215.	1.0	2
166	Pattern and characteristics of advanced cancer patients admitted to hospices in Italy. Supportive Care in Cancer, 2013, 21, 935-939.	1.0	28
167	Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies. Current Medical Research and Opinion, 2013, 29, 667-671.	0.9	31
168	The long and winding road of non steroidal antinflammatory drugs and paracetamol in cancer pain management: A critical review. Critical Reviews in Oncology/Hematology, 2013, 87, 140-145.	2.0	30
169	Orphan symptoms in advanced cancer patients followed at home. Supportive Care in Cancer, 2013, 21, 3525-3528.	1.0	17
170	Changes of QTc interval after opioid switching to oral methadone. Supportive Care in Cancer, 2013, 21, 3421-3424.	1.0	12
171	Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opinion on Investigational Drugs, 2013, 22, 161-166.	1.9	32
172	Prognostic Factors of Survival in Patients With Advanced Cancer Admitted to Home Care. Journal of Pain and Symptom Management, 2013, 45, 56-62.	0.6	39
173	Opioid Switching in Patients With Advanced Cancer Followed at Home. A Retrospective Analysis. Journal of Pain and Symptom Management, 2013, 45, 298-304.	0.6	20
174	The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Current Medical Research and Opinion, 2013, 29, 1527-1532.	0.9	25
175	Cancer pain. Current Opinion in Supportive and Palliative Care, 2013, 7, 139-143.	0.5	14
176	Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Current Medical Research and Opinion, 2013, 29, 93-97.	0.9	39
177	Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Current Medical Research and Opinion, 2013, 29, 661-666.	0.9	42
178	The Effects of Low Doses of Pregabalin on Morphine Analgesia in Advanced Cancer Patients. Clinical Journal of Pain, 2013, 29, 15-19.	0.8	19
179	Research in Palliative Care: My Past, My Present, My Future. Journal of Palliative Care & Medicine, 2013, 03, .	0.1	1
180	For a Modern Concept of Palliative Care. Journal of Palliative Care & Medicine, 2013, 02, .	0.1	0

#	Article	IF	Citations
181	Intravenous Use of Methadone: Efficacy and Safety. , 2013, , 81-89.		O
182	Ketamine: to be or not to be. Annals of Palliative Medicine, 2013, 2, 37-9.	0.5	6
183	Opioid combination: rationale and possible clinical applications. Annals of Palliative Medicine, 2013, 2, 189-96.	0.5	9
184	Tapentadol in cancer pain management: a prospective open-label study. Current Medical Research and Opinion, 2012, 28, 1775-1779.	0.9	57
185	Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. Expert Opinion on Pharmacotherapy, 2012, 13, 873-878.	0.9	8
186	Palliative Care in Advanced Cancer Patients: How and When? And Where?. Oncologist, 2012, 17, e10-e11.	1.9	2
187	Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology, The, 2012, 13, e58-e68.	5.1	1,017
188	Emergencies in Patients With Advanced Cancer Followed at Home. Journal of Pain and Symptom Management, 2012, 44, 295-300.	0.6	39
189	Switching From Methadone to Tapentadol for Cancer Pain. Journal of Pain and Symptom Management, 2012, 44, e3-e5.	0.6	3
190	Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Current Medical Research and Opinion, 2012, 28, 963-968.	0.9	52
191	Cancer pain undertreatment and prognostic factors. Pain, 2012, 153, 1770-1771.	2.0	6
192	The Effect of Age on Opioid Switching to Methadone: A Systematic Review. Journal of Palliative Medicine, 2012, 15, 347-351.	0.6	15
193	Pharmacotherapy for Breakthrough Cancer Pain. Drugs, 2012, 72, 181-190.	4.9	104
194	The Author's Reply. Drugs, 2012, 72, 1009-1010.	4.9	0
195	US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids. Drugs, 2012, 72, 2327-2332.	4.9	17
196	Octreotide for malignant bowel obstruction: Twenty years after. Critical Reviews in Oncology/Hematology, 2012, 83, 388-392.	2.0	42
197	Clarifications on oxycodone–naloxone combination in cancer pain management. Supportive Care in Cancer, 2012, 20, 1351-1352.	1.0	3
198	Spinal analgesia for advanced cancer patients: An update. Critical Reviews in Oncology/Hematology, 2012, 82, 227-232.	2.0	18

#	Article	IF	CITATIONS
199	Switching Methadone: A 10-Year Experience of 345 Patients in an Acute Palliative Care Unit. Pain Medicine, 2012, 13, 399-404.	0.9	45
200	Episodic (Breakthrough) Pain Prevalence in a Population of Cancer Pain Patients. Comparison of Clinical Diagnoses With the QUDEI—Italian Questionnaire for Intense Episodic Pain. Journal of Pain and Symptom Management, 2012, 43, 833-841.	0.6	62
201	Palliative Sedation in Advanced Cancer Patients Followed at Home: A Retrospective Analysis. Journal of Pain and Symptom Management, 2012, 43, 1126-1130.	0.6	33
202	Switching from oxycodone to methadone in advanced cancer patients. Supportive Care in Cancer, 2012, 20, 191-194.	1.0	16
203	Opioid-induced hyperalgesia after rapid titration with intravenous morphine: Switching and re-titration to intravenous methadone. Annals of Palliative Medicine, 2012, 1, 10-3.	0.5	14
204	Outcome of opioid switching 4 weeks after discharge from a palliative care unit. Current Medical Research and Opinion, 2011, 27, 2357-2360.	0.9	7
205	Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliative Medicine, 2011, 25, 504-515.	1.3	157
206	The Use of High Doses of Oxycodone in an Acute Palliative Care Unit. American Journal of Hospice and Palliative Medicine, 2011, 28, 242-244.	0.8	14
207	Does pain intensity predict a poor opioid response in cancer patients?. European Journal of Cancer, 2011, 47, 713-717.	1.3	18
208	Effectiveness and Tolerability of Amidotrizoate for the Treatment of Constipation Resistant to Laxatives in Advanced Cancer Patients. Journal of Pain and Symptom Management, 2011, 41, 421-425.	0.6	11
209	Refractory Death Rattle: Deep Aspiration Facilitates the Effects of Antisecretory Agents. Journal of Pain and Symptom Management, 2011, 41, 637-639.	0.6	13
210	Palliative Sedation in Patients with Advanced Cancer Followed at Home: A Systematic Review. Journal of Pain and Symptom Management, 2011, 41, 754-760.	0.6	87
211	Fentanyl Buccal Tablets for Breakthrough Pain in Highly Tolerant Cancer Patients: Preliminary Data on the Proportionality Between Breakthrough Pain Dose and Background Dose. Journal of Pain and Symptom Management, 2011, 42, 464-469.	0.6	38
212	How Do Cancer Patients Receiving Palliative Care at Home Die? A Descriptive Study. Journal of Pain and Symptom Management, 2011, 42, 702-709.	0.6	37
213	The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing. Critical Reviews in Oncology/Hematology, 2011, 80, 460-465.	2.0	74
214	Rapid onset opioids for breakthrough pain: Titrating or not titrating, this is the question!. European Journal of Pain Supplements, 2011, 5, 443-447.	0.0	10
215	The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. Supportive Care in Cancer, 2011, 19, 435-438.	1.0	9
216	An Italian survey on the attitudes in treating breakthrough cancer pain in hospice. Supportive Care in Cancer, 2011, 19, 979-983.	1.0	19

#	Article	IF	CITATIONS
217	High doses of oxycodone–naloxone combination may provide poor analgesia. Supportive Care in Cancer, 2011, 19, 1471-1472.	1.0	36
218	Emerging drugs for cancer-related pain. Supportive Care in Cancer, 2011, 19, 1887-1893.	1.0	9
219	Managing Breakthrough Pain. Current Pain and Headache Reports, 2011, 15, 244-249.	1.3	21
220	Fentanyl buccal tablets for the treatment of breakthrough pain. Pain Management, 2011, 1, 533-538.	0.7	0
221	The use of high doses of OROS hydromorphone in an acute palliative care unit. Current Medical Research and Opinion, 2011, 27, 2373-2376.	0.9	1
222	Sexuality in Patients With Advanced Cancer: A Prospective Study in a Population Admitted to an Acute Pain Relief and Palliative Care Unit. American Journal of Hospice and Palliative Medicine, 2011, 28, 198-202.	0.8	29
223	Prevalence of Opioid-Related Dysuria in Patients With Advanced Cancer Having Pain. American Journal of Hospice and Palliative Medicine, 2011, 28, 27-30.	0.8	11
224	Prospects and challenges in opioid analgesia for pain management. Current Medical Research and Opinion, 2011, 27, 1741-1743.	0.9	15
225	NIV Outside the ICU., 2011,, 623-629.		1
226	When the Progression of Disease Lowers Opioid Requirement in Cancer Patients. Clinical Journal of Pain, 2010, 26, 56-57.	0.8	3
227	The Use of Opioids for Breakthrough Pain in Acute Palliative Care Unit by Using Doses Proportional to Opioid Basal Regimen. Clinical Journal of Pain, 2010, 26, 306-309.	0.8	33
228	Morphine Versus Oxycodone in Pancreatic Cancer Pain. Clinical Journal of Pain, 2010, 26, 794-797.	0.8	46
229	Sexual issues in early and late stage cancer: a review. Supportive Care in Cancer, 2010, 18, 659-665.	1.0	81
230	Management of cancer pain. Internal and Emergency Medicine, 2010, 5, 31-35.	1.0	21
231	Breakthrough Pain in Oncology: AÂLongitudinal Study. Journal of Pain and Symptom Management, 2010, 40, 183-190.	0.6	55
232	Intravenous patient-controlled analgesia and management of pain in post-surgical elderly with cancer. Surgical Oncology, 2010, 19, 173-177.	0.8	13
233	The Role of OROSÃ,®Hydromorphone in the Management of Cancer Pain. Pain Practice, 2010, 10, 72-77.	0.9	14
234	Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile. Pain Practice, 2010, 10, 428-450.	0.9	244

#	Article	IF	CITATIONS
235	Breakthrough Pain. Current Drug Therapy, 2010, 5, 62-66.	0.2	O
236	The Use of Opioids in the Last Week of Life in an Acute Palliative Care Unit. American Journal of Hospice and Palliative Medicine, 2010, 27, 514-517.	0.8	8
237	Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Current Medical Research and Opinion, 2010, 26, 2765-2768.	0.9	21
238	Pain in patients with lung cancer: Pathophysiology and treatment. Lung Cancer, 2010, 68, 10-15.	0.9	34
239	Intravenous morphine for management of cancer pain. Lancet Oncology, The, 2010, 11, 484-489.	5.1	71
240	Effects of Red Blood Cell Transfusion on Anemia-Related Symptoms in Patients with Cancer. Journal of Palliative Medicine, 2009, 12, 60-63.	0.6	60
241	Frequency, Indications, Outcomes, and Predictive Factors of Opioid Switching in an Acute Palliative Care Unit. Journal of Pain and Symptom Management, 2009, 37, 632-641.	0.6	129
242	High-Dose Furosemide and Small-Volume Hypertonic Saline Solution Infusion for the Treatment of Leg Edema in Advanced Cancer Patients. Journal of Pain and Symptom Management, 2009, 37, 419-423.	0.6	12
243	Controlled Sedation for Refractory Symptoms in Dying Patients. Journal of Pain and Symptom Management, 2009, 37, 771-779.	0.6	109
244	Breakthrough Pain in Advanced Cancer Patients Followed at Home: A Longitudinal Study. Journal of Pain and Symptom Management, 2009, 38, 554-560.	0.6	40
245	Noninvasive Ventilation for the Treatment of Dyspnea as a Bridge from Intensive to End-of-Life Care. Journal of Pain and Symptom Management, 2009, 38, e5-e7.	0.6	6
246	Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational study. Clinical Therapeutics, 2009, 31, 2134-2138.	1.1	22
247	Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Supportive Care in Cancer, 2009, 17, 715-718.	1.0	43
248	Breakthrough pain: On the road again. European Journal of Pain, 2009, 13, 329-330.	1.4	35
249	Treatment strategies for cancer patients with breakthrough pain. Expert Opinion on Pharmacotherapy, 2009, 10, 947-953.	0.9	13
250	Tools for Identifying Cancer Pain of Predominantly Neuropathic Origin and Opioid Responsiveness in Cancer Patients. Journal of Pain, 2009, 10, 594-600.	0.7	65
251	The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Current Medical Research and Opinion, 2009, 25, 1517-1528.	0.9	56
252	Opioid Switching and Burst Ketamine to Improve the Opioid Response in Patients With Movement-related Pain Due to Bone Metastases. Clinical Journal of Pain, 2009, 25, 648-649.	0.8	25

#	Article	IF	CITATIONS
253	Intestinal Dysfunction and Obstruction. , 2009, , 1267-1275.		6
254	A Randomized-Controlled Study of Intrathecal Versus Epidural Thoracic Analgesia in Patients Undergoing Abdominal Cancer Surgery. Journal of Clinical Monitoring and Computing, 2008, 22, 293-298.	0.7	9
255	Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Supportive Care in Cancer, 2008, 16, 975-978.	1.0	33
256	Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey. Supportive Care in Cancer, 2008, 16, 1203-1211.	1.0	30
257	Sustainedâ€release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain, 2008, 12, 1040-1046.	1.4	117
258	Intravenous Morphine for Breakthrough (Episodic-) Pain in an Acute Palliative Care Unit: A Confirmatory Study. Journal of Pain and Symptom Management, 2008, 35, 307-313.	0.6	45
259	Bedside Anesthesia for Painful Procedures in Onco-Hematology. Journal of Palliative Medicine, 2008, 11, 8-9.	0.6	1
260	Cancer Pain. , 2008, , 113-128.		0
261	Why are our patients still suffering pain?. Nature Clinical Practice Oncology, 2007, 4, 138-139.	4.3	10
262	Opioid Plasma Concentrations during a Switch from Transdermal Fentanyl to Methadone. Journal of Palliative Medicine, 2007, 10, 338-344.	0.6	17
263	Injustifiable use of gastroprotection in advanced cancer patients. Palliative Medicine, 2007, 21, 631-633.	1.3	4
264	Management of painful bone metastases. Current Opinion in Oncology, 2007, 19, 308-314.	1.1	124
265	Intrathecal Treatment in Cancer Patients Unresponsive to Multiple Trials of Systemic Opioids. Clinical Journal of Pain, 2007, 23, 793-798.	0.8	92
266	Pharmacological Management of Cancer Pain in the Elderly. Drugs and Aging, 2007, 24, 761-776.	1.3	69
267	Opioid titration in cancer pain: A critical review. European Journal of Pain, 2007, 11, 823-830.	1.4	60
268	Medical Treatment for Inoperable Malignant Bowel Obstruction: A Qualitative Systematic Review. Journal of Pain and Symptom Management, 2007, 33, 217-223.	0.6	109
269	Switching from Transdermal Drugs: An Observational "N of 1―Study of Fentanyl and Buprenorphine. Journal of Pain and Symptom Management, 2007, 34, 532-538.	0.6	33
270	About Pain, Opioids, and Dialysis. Journal of Pain and Symptom Management, 2007, 34, 5-6.	0.6	3

#	Article	IF	CITATIONS
271	Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Supportive Care in Cancer, 2007, 15, 441-444.	1.0	38
272	Fentanyl Buccal Tablet in Breakthrough Pain in Opioid-Tolerant Patients with Cancer. Drugs, 2006, 66, 2394-2395.	4.9	4
273	Opioid switching: A systematic and critical review. Cancer Treatment Reviews, 2006, 32, 304-315.	3.4	231
274	Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?. European Journal of Pain, 2006, 10, 153-153.	1.4	32
275	Scoring the effect of radiotherapy for painful bone metastases. Supportive Care in Cancer, 2006, 14, 967-969.	1.0	21
276	Low Morphine Doses in Opioid-Naive Cancer Patients with Pain. Journal of Pain and Symptom Management, 2006, 31, 242-247.	0.6	74
277	Safety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine. Journal of Pain and Symptom Management, 2006, 32, 175-179.	0.6	72
278	Opioid Escalation in Patients with Cancer Pain: The Effect of Age. Journal of Pain and Symptom Management, 2006, 32, 413-419.	0.6	38
279	Local Anesthetics for Breakthrough Pain in Patients Receiving Intrathecal Treatment for Cancer Pain Management. Anesthesia and Analgesia, 2005, 100, 1540.	1.1	4
280	Problematic Discharge from Hospital for Patients Prescribed Opioids for Cancer Pain. Journal of Pain and Symptom Management, 2005, 29, 433-434.	0.6	2
281	Patients' and Relatives' Perceptions About Intravenous and Subcutaneous Hydration. Journal of Pain and Symptom Management, 2005, 30, 354-358.	0.6	64
282	Alternative Treatments of Breakthrough Pain in Patients Receiving Spinal Analgesics for Cancer Pain. Journal of Pain and Symptom Management, 2005, 30, 485-491.	0.6	59
283	Incidence of Chronic Pain in Patients with End-Stage Renal Disease on Dialysis. Journal of Pain and Symptom Management, 2005, 30, 302-304.	0.6	28
284	Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain. Supportive Care in Cancer, 2005, 13, 702-707.	1.0	26
285	Rapid Switching Between Transdermal Fentanyl and Methadone in Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5229-5234.	0.8	71
286	Hyperalgesia and opioid switching. American Journal of Hospice and Palliative Medicine, 2005, 22, 291-294.	0.8	76
287	Cancer pain management in children. Palliative Medicine, 2004, 18, 654-662.	1.3	38
288	Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. Journal of Pain and Symptom Management, 2004, 27, 352-359.	0.6	72

#	Article	lF	CITATIONS
289	Aggressive pharmacological treatment for reversing malignant bowel obstruction. Journal of Pain and Symptom Management, 2004, 28, 412-416.	0.6	96
290	Optimization of opioid therapy for preventing incident pain associated with bone metastases. Journal of Pain and Symptom Management, 2004, 28, 505-510.	0.6	103
291	Factors involved in gastrointestinal bleeding in advanced cancer patients followed at home. Supportive Care in Cancer, 2004, 12, 95-98.	1.0	7
292	Dialogues on complex analgesic strategies for difficult pain syndromes. Supportive Care in Cancer, 2004, 12, 599-603.	1.0	4
293	Sleep disorders in advanced cancer patients: prevalence and factors associated. Supportive Care in Cancer, 2004, 12, 355-359.	1.0	101
294	Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Supportive Care in Cancer, 2004, 12, 762-766.	1.0	62
295	Opioids and renal function. Journal of Pain, 2004, 5, 2-19.	0.7	116
296	To the Editor. Journal of Pain, 2004, 5, 138-139.	0.7	2
297	A model of acute symptom control unit: Pain Relief and Palliative Care Unit of La Maddalena Cancer Center. Supportive Care in Cancer, 2003, 11, 114-119.	1.0	34
298	Burst Ketamine to Reverse Opioid Tolerance in Cancer Pain. Journal of Pain and Symptom Management, 2003, 25, 302-305.	0.6	46
299	Hyperalgesia: An Emerging latrogenic Syndrome. Journal of Pain and Symptom Management, 2003, 26, 769-775.	0.6	139
300	Celiac plexus block for pancreatic cancer pain: factors influencing pain, symptoms and quality of life. Journal of Pain and Symptom Management, 2003, 26, 1140-1147.	0.6	49
301	Sympathetic blocks and disease progression modifying pain mechanisms. Regional Anesthesia and Pain Medicine, 2003, 28, 586-587.	1.1	2
302	Sympathetic Blocks and Disease Progression Modifying Pain Mechanisms. Regional Anesthesia and Pain Medicine, 2003, 28, 586-587.	1.1	3
303	Opioid prescription in Italy: new law, no effect. Lancet, The, 2002, 360, 1254-1255.	6.3	24
304	CT-Guided Neurolytic Splanchnic Nerve Block by an Anterior Approach. Journal of Pain and Symptom Management, 2002, 23, 268-270.	0.6	8
305	Episodic (breakthrough) pain. Cancer, 2002, 94, 832-839.	2.0	313
306	Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer, 2002, 95, 203-208.	2.0	81

#	Article	IF	Citations
307	Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori, 2002, 88, 239-42.	0.6	24
308	Pain mechanisms involved and outcome in advanced cancer patients with possible indications for celiac plexus block and superior hypogastric plexus block. Tumori, 2002, 88, 243-5.	0.6	9
309	Breakthrough pain. , 2001, , 506-514.		O
310	Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report. Journal of Clinical Oncology, 2001, 19, 2542-2554.	0.8	582
311	Switching From Morphine to Methadone to Improve Analgesia and Tolerability in Cancer Patients: A Prospective Study. Journal of Clinical Oncology, 2001, 19, 2898-2904.	0.8	237
312	Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Supportive Care in Cancer, 2001, 9, 223-233.	1.0	275
313	Opioid Poorly-Responsive Cancer Pain. Part 1. Journal of Pain and Symptom Management, 2001, 21, 144-150.	0.6	117
314	Opioid Poorly-Responsive Cancer Pain. Part 2. Journal of Pain and Symptom Management, 2001, 21, 255-264.	0.6	63
315	Assessing Delirium in Cancer Patients. The Italian Versions of the Delirium Rating Scale and the Memorial Delirium Assessment Scale. Journal of Pain and Symptom Management, 2001, 21, 59-68.	0.6	70
316	Opioid Poorly-Responsive Cancer Pain. Part 3. Clinical Strategies to Improve Opioid Responsiveness. Journal of Pain and Symptom Management, 2001, 21, 338-354.	0.6	86
317	Pamidronate in Incident Pain Due to Bone Metastases. Journal of Pain and Symptom Management, 2001, 22, 630-631.	0.6	15
318	Opioid Responsiveness-Primary Diagnosis Relationship in Advanced Cancer Patients Followed At Home. Journal of Pain and Symptom Management, 2000, 20, 27-34.	0.6	20
319	The Course of Symptom Frequency and Intensity in Advanced Cancer Patients Followed at Home. Journal of Pain and Symptom Management, 2000, 20, 104-112.	0.6	148
320	Analgesic Effect of Intravenous Ketamine in Cancer Patients on Morphine Therapy. Journal of Pain and Symptom Management, 2000, 20, 246-252.	0.6	233
321	Opioid Nonresponsiveness in Cancer Pain Can Be Reversible. A Serendipitous Conclusion of a Retrospective Analysis. Journal of Pain and Symptom Management, 2000, 20, 393-394.	0.6	2
322	Role of Octreotide, Scopolamine Butylbromide, and Hydration in Symptom Control of Patients with Inoperable Bowel Obstruction and Nasogastric Tubes. Journal of Pain and Symptom Management, 2000, 19, 23-34.	0.6	189
323	Gastrointestinal Bleeding In Advanced Cancer Patients. Journal of Pain and Symptom Management, 2000, 19, 160-162.	0.6	6
324	The impact of home palliative care on symptoms in advanced cancer patients. Supportive Care in Cancer, 2000, 8, 307-310.	1.0	43

#	Article	IF	CITATIONS
325	Rapid Switching From Morphine to Methadone in Cancer Patients With Poor Response to Morphine. Journal of Clinical Oncology, 1999, 17, 3307-3312.	0.8	134
326	The role of morphine glucuronides in cancer pain. Palliative Medicine, 1999, 13, 95-104.	1.3	37
327	Methadone Response in Advanced Cancer Patients with Pain Followed at Home. Journal of Pain and Symptom Management, 1999, 18, 188-192.	0.6	46
328	Investigation of an Opioid Response Categorization in Advanced Cancer Patients. Journal of Pain and Symptom Management, 1999, 18, 347-352.	0.6	54
329	Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. , 1999, 85, 1849-1858.		128
330	Opioid rotation for cancer pain., 1999, 86, 1856-1866.		291
331	Problems of long-term spinal opioid treatment in advanced cancer patients. Pain, 1999, 79, 1-13.	2.0	151
332	Temporary Drainage of Symptomatic Malignant Ascites by a Catheter Inserted Under Computerized Tomography. Journal of Pain and Symptom Management, 1998, 15, 374-378.	0.6	8
333	Dextropropoxyphene versus morphine in Opioid-Naive cancer patients with pain. Journal of Pain and Symptom Management, 1998, 15, 76-81.	0.6	57
334	Opioid responsiveness in patients with advanced head and neck cancer. Supportive Care in Cancer, 1998, 6, 482-485.	1.0	19
335	Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain, 1998, 74, 5-9.	2.0	87
336	Malignant bone pain: pathophysiology and treatment. Pain, 1997, 69, 1-18.	2.0	744
337	Monitoring of opioid therapy in advanced cancer pain patients. Journal of Pain and Symptom Management, 1997, 13, 204-212.	0.6	76
338	Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. Journal of Pain and Symptom Management, 1997, 13, 241-244.	0.6	33
339	The inappropriate use of the epidural route in cancer pain. Journal of Pain and Symptom Management, 1997, 13, 233-237.	0.6	18
340	Octreotide may prevent definitive intestinal obstruction. Journal of Pain and Symptom Management, 1997, 13, 352-355.	0.6	41
341	Nutrition in cancer patients. Supportive Care in Cancer, 1996, 4, 10-20.	1.0	32
342	Bowel obstruction in home-care cancer patients: 4 years experience. Supportive Care in Cancer, 1995, 3, 190-193.	1.0	44

#	Article	IF	CITATIONS
343	Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. Journal of Pain and Symptom Management, 1994, 9, 201-207.	0.6	54
344	Pain characteristics of advanced lung cancer patients referred to a palliative care service. Pain, 1994, 59, 141-145.	2.0	54
345	Celiac plexus block versus analgesics in pancreatic cancer pain. Pain, 1993, 52, 187-192.	2.0	189
346	Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliative Medicine, 1993, 7, 295-299.	1.3	115
347	Predictive factors in advanced cancer pain treated only by analgesics. Pain, 1992, 50, 151-155.	2.0	113
348	Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. Journal of Pain and Symptom Management, 1992, 7, 496-498.	0.6	56
349	Commentary: Interpreting Data of Celiac Plexus Block in Patients with Pancreatic Pain: Timing, Patients, Survival. Pain and Therapy, 0, , .	1.5	2